Wade T. Iams, MD

Wade Iams, MD, MSCI, of Tennessee Oncology, presents the first clinical scenario in this OncLive My Treatment Approach discussion with Edgardo Santos, MD, FACP, FASCO, of Starling Oncology: a 58-year-old woman who never smoked, with a 6-week history of progressive cough.

Wade Iams, MD, MSCI, of Tennessee Oncology, describes how he opens the first treatment conversation with patients who have EGFR-mutated advanced non–small cell lung cancer and with their families, after Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, notes that grade 3 or higher adverse events were more common with amivantamab plus lazertinib than with osimertinib in MARIPOSA.

Experts compare first-line EGFR-mutated NSCLC regimens, showing why subcutaneous amivantamab+lazertinib and chemo+osimertinib boost survival.

Compare first-line EGFR-mutant NSCLC options, weighing amivantamab–lazertinib vs chemo–osimertinib, plus practical start-up and prevention tips.

Learn practical systems for managing EGFR therapy side effects, triage tips, and what’s next for resistance in metastatic NSCLC.

Experts weigh EGFR L858R/TP53 stage IV NSCLC options, combo regimens and brain-met strategies to boost control, ease visits.

Experts weigh combo therapy for EGFR L858R/TP53 lung cancer with brain mets, balancing radiation and systemic options to cut visits.

Experts compare EGFR lung cancer first-line combos, weighing chemo vs amivantamab-lazurtnib toxicity, quality of life, and patient-centered choice.

Experts weigh NCCN category 1 value and show how serial brain MRIs shape EGFR lung cancer first-line treatment decisions.

This episode explores how overall survival data, toxicity profiles, and guideline categorizations inform frontline decision-making.

This segment frames the current first-line treatment landscape for EGFR-mutant metastatic non–small cell lung cancer and how it has evolved over two decades.

Wade Iams, MD, MSCI, discusses the management of LEMS in the context of SCLC.

Oncologists explore the challenges of distinguishing between chemotherapy fatigue and cancer-related limb pain, emphasizing the need for effective screening tools.

Experts discuss diagnosing Lambert-Eaton Myasthenic Syndrome, emphasizing clinical features, serologic tests, and the importance of neurologist involvement.

Oncologists and neurologists enhance patient care through effective collaboration, early screening, and utilizing specialized resources for cancer-associated conditions.

Oncologists explore updated NCCN guidelines for diagnosing neurologic paraneoplastic syndromes in small cell lung cancer, emphasizing multidisciplinary care.

Explore effective treatment monitoring strategies for amifampridine, including side effects management and titration techniques for optimal patient care.

Oncologists explore the challenges of distinguishing between chemotherapy fatigue and cancer-related limb pain, emphasizing the need for effective screening tools.

Panelists discuss how CA-LEMS biology reflects an off-target antitumor immune response (often with SCLC) that generates antibodies against presynaptic VGCCs, reducing acetylcholine release and causing proximal weakness with brief strength improvement after repeated activation.

Panelists discuss how early segment-level recognition of CA-LEMS hinges on spotting hallmark clinical cues (proximal lower-extremity weakness, autonomic dysfunction, and reflexes that transiently improve after exercise) and not dismissing symptoms as deconditioning or cancer-treatment effects, given frequent links to SCLC and other malignancies.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss ongoing research in early-stage non–small cell lung cancer.

Panelists discuss how future advances will focus on biomarker-driven personalized approaches, platform trials to increase pathologic complete response rates, circulating tumor DNA (ctDNA)-guided therapy escalation and de-escalation, and the critical importance of comprehensive molecular testing in the neoadjuvant setting.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy could continue to reshape early NSCLC management.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss factors that affect adjuvant treatment decisions in early non–small cell lung cancer.

Panelists discuss how the PACIFIC-R real-world data demonstrates excellent long-term outcomes with a median survival of 60 months, validating the durvalumab consolidation approach while addressing management strategies for patients who progress on or after immunotherapy.

Panelists discuss how neoadjuvant chemoimmunotherapy maintains acceptable surgical safety profiles with mortality rates under 4% and how technical complexity primarily stems from hilar lymph node involvement rather than the systemic therapy itself, requiring experienced surgeons to handle these cases.

Panelists discuss how circulating tumor DNA (ctDNA) serves as a promising biomarker for identifying patients at higher risk who may benefit from therapy escalation, though they acknowledge the current lack of prospective data on how to act therapeutically on positive ctDNA results.

Panelists discuss how treatment decisions should integrate multiple factors, including pathologic complete response (pCR), PD-L1 status, and nodal involvement, with particular emphasis on continuing adjuvant therapy for N2 disease and non-PCR patients despite the complexity of using residual viable tumor as a decision-making tool.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated findings for neoadjuvant nivolumab plus chemotherapy in resectable NSCLC.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss surgical outcomes from CheckMate-77T for perioperative nivolumab in resectable NSCLC.